BENGALURU, Feb 3 (Reuters) - Indian pharmaceutical firm
Divi's Laboratories Ltd DIVI.NS on Friday reported a
third-quarter profit that widely missed analysts' estimates,
hurt by higher inventory costs, and sent its shares tumbling
more than 13%.
The Hyderabad-based company said consolidated net profit for
the three months ended Dec. 31 was 3.07 billion rupees ($37.34
million), down from 9.02 billion rupees last year.
Analysts on an average had expected the company, which makes
drug ingredients, to report a profit of 5.33 billion rupees.
Shares of Divi's Labs slumped as much as 13.6% to 2,822.70
rupees to post their biggest intraday percentage loss since
March 2020.
Divi's makes active pharmaceutical ingredients which are key
biologically active elements in a drug that help with the
desired health effects. The company also makes chemical
substances used to make drugs.
Consolidated revenue from operations for the company,
declined 31.5% from last year, while inventory costs in the
third quarter were at 1.23 billion rupees.
Smaller rival Laurus Labs Ltd LAUL.NS earlier this week
reported a 32.1% jump in third-quarter profit, boosted by strong
demand in its businesses that make chemicals and other
ingredients used in medicines.
($1 = 82.2250 Indian rupees)
(Reporting by Rama Venkat in Bengaluru; editing by Eileen
Soreng)
((ramavenkat.raman@thomsonreuters.com; https://twitter.com/ramavenkat0607;))